CD8A and neoplasm: In preclinical models of various cancers, CSF1R inhibitors (e.g., Pexidartinib, PLX3397) can effectively deplete or repolarize TAMs, reduce M2-type macrophages, and promote CD8+ T cell tumor infiltration, thereby exerting antitumor effects (141, 142).